Biocon Biologics, a subsidiary of Biocon has announced that UK Medicines and Healthcare products Regulatory Agency (UK MHRA), has granted marketing authorization for Yesafili, a biosimilar of aflibercept.
In September, Yesafili, received marketing authorization approval from the European Commission (EC) for the European Union (EU).
Yesafili, an ophthalmology product, is intended for the treatment of neovascular (wet AMD) age-related macular degeneration, visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO), visual impairment due to diabetic macular oedema (DME) and visual impairment due to myopic choroidal neovascularisation (myopic CNV). It is highly similar to the reference product Eylea (aflibercept). Data shows that Yesafili has comparable quality, safety, and efficacy to Eylea.
“We are very pleased to receive the MHRA approval for Yesafili, biosimilar aflibercept, which will enable us to address the needs of patients impacted by macular degeneration and diabetic retinopathy, in the UK. This approval will expand our biosimilar offerings to patients across the globe, building on our oncology and diabetes product portfolios," company spokesperson said.
